Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928183 | 0.78 | CRBN (0.42) | DDB1CRBNGBA1PDE10APOLB | |
| SCHEMBL2653607 | 0.73 | GBA1 (0.46) | DDB1CRBNGBA1POLB | |
| SCHEMBL15633020 | 0.68 | RAB9A (0.42) | DDB1CRBNGBA1 | |
| SCHEMBL13173479 | 0.67 | HRH1 (0.38) | DDB1CRBNGBA1POLB | |
| SCHEMBL211656 | 0.67 | — | — | |
| SCHEMBL21495203 | 0.66 | KDM4E (0.41) | DDB1CRBNGBA1 | |
| SCHEMBL11731794 | 0.66 | ALDH1A1 (0.45) | DDB1CRBNGBA1 | |
| SCHEMBL18128057 | 0.66 | GBA1 (0.34) | DDB1CRBNGBA1POLB | |
| SCHEMBL640212 | 0.65 | DDB1 (0.53) | DDB1CRBNGBA1 | |
| SCHEMBL2995142 | 0.65 | L3MBTL1 (0.48) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3319942-B1 | ROR-GAMMA MODULATORS | LEAD PHARMA B V (NL) | 2020-03-11 | — | — | EP | disclosed |
| US-20190040012-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2019-02-07 | — | — | US | disclosed |
| US-10118895-B2 | ROR gamma (RORγ) modulators | LEAD PHARMA HOLDING B.V. (NL) | 2018-11-06 | — | — | US | disclosed |
| US-20180141909-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2018-05-24 | — | — | US | disclosed |
| EP-3319942-A1 | ROR GAMMA (RORY) MODULATORS | Lead Pharma Holding B.V. (NL) | 2018-05-16 | — | — | EP | disclosed |
| WO-2016193468-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040012-A1 | ROR GAMMA (RORY) MODULATORS | RORC, RORA, RORB | DDB1 2855/4885CRBN 276/4885GBA1 2257/4885 |
| US-20180141909-A1 | ROR GAMMA (RORY) MODULATORS | RORC, RORA, RORB | DDB1 3046/4885CRBN 239/4885GBA1 2591/4885 |
| US-10118895-B2 | ROR gamma (RORγ) modulators | RORC, RORA, RORB | DDB1 3393/4885CRBN 263/4885GBA1 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.